Aculys Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 15

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $35M

Aculys General Information

Description

Operator of a clinical-stage biopharmaceutical company intended to eliminate drug lag/drug loss in Japan and is working to resolve social issues related to neurological and psychiatric diseases. The company creates drugs that are aimed at helping patients who are suffering from debilitating neurologic diseases and specializes in central nervous system treatment, enabling patients to improve their quality of life.

Contact Information

Website
www.aculys.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 2-14-4 Kita-Aoyama
  • Minato-ku
  • Tokyo
  • Japan
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Viatris
Vertical(s)
Corporate Office
  • 2-14-4 Kita-Aoyama
  • Minato-ku
  • Tokyo
  • Japan

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aculys Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 15-Oct-2025 $35M Completed Clinical Trials - Phase 3
4. Later Stage VC (Series C) 11-Feb-2025 Completed Clinical Trials - Phase 3
3. Early Stage VC (Series B) 22-Feb-2022 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A) 28-Oct-2021 $61.3M $64.5M Completed Startup
1. Seed Round 28-Oct-2021 $3.2M $3.2M Completed Startup
To view Aculys’s complete valuation and funding history, request access »

Aculys Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
C Preferred
B Preferred
A Preferred 9,457,958 $4.72 $4.72 1x $4.72 47.92%
To view Aculys’s complete cap table history, request access »

Aculys Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage biopharmaceutical company intended to eliminate drug lag/drug loss in Japan and is working
Drug Discovery
Tokyo, Japan
15 As of 2025

London, United Kingdom
 

Oss, Netherlands
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Aculys Competitors (16)

One of Aculys’s 16 competitors is Neurentis, a Corporation company based in London, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Neurentis Corporation London, United Kingdom
Citryll Venture Capital-Backed Oss, Netherlands
Intracellular Therapies Formerly VC-backed Bedminster, NJ
Cristal Therapeutics Venture Capital-Backed Maastricht, Netherlands
TheraVida Venture Capital-Backed Chapel Hill, NC
You’re viewing 5 of 16 competitors. Get the full list »

Aculys Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aculys Former Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
ANRI Venture Capital Minority
Catalys Pacific Venture Capital Minority
Global Founders Capital Venture Capital Minority
HBM Healthcare Investments Venture Capital Minority
HBM Partners Venture Capital Minority
You’re viewing 5 of 14 investors. Get the full list »

Aculys FAQs

  • When was Aculys founded?

    Aculys was founded in 2021.

  • Where is Aculys headquartered?

    Aculys is headquartered in Tokyo, Japan.

  • What is the size of Aculys?

    Aculys has 15 total employees.

  • What industry is Aculys in?

    Aculys’s primary industry is Drug Discovery.

  • Is Aculys a private or public company?

    Aculys is a Private company.

  • What is the current valuation of Aculys?

    The current valuation of Aculys is .

  • What is Aculys’s current revenue?

    The current revenue for Aculys is .

  • How much funding has Aculys raised over time?

    Aculys has raised $118M.

  • Who are Aculys’s investors?

    ANRI, Catalys Pacific, Global Founders Capital, HBM Healthcare Investments, and HBM Partners are 5 of 14 investors who have invested in Aculys.

  • Who are Aculys’s competitors?

    Neurentis, Citryll, Intracellular Therapies, Cristal Therapeutics, and TheraVida are some of the 16 competitors of Aculys.

  • When was Aculys acquired?

    Aculys was acquired on 15-Oct-2025.

  • Who acquired Aculys?

    Aculys was acquired by Viatris.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process